8月6日 - ** Scholar Rock（SRRK.O）股价在盘前交易中上涨9.69%，至52.51美元
** 第二季度每股净亏损为0.84美元，而去年同期为每股0.98美元
** 公司表示，其脊髓性肌萎缩症药物的申请正在接受FDA审查，进展持续推进，目前有两家灌装和包装工厂，这意味着有两条独立的审批路径，预计最迟将于9月30日作出决定
** 补充称，公司已做好准备，一旦获得FDA批准，将立即在美国推出该药物apitegromab；商业化所需供应充足
** 截至2026年6月30日，SRRK持有现金、现金等价物及有价证券共计4.921亿美元
** 截至上一交易日收盘，该股年内累计涨幅约9%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.